U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C25H23F3N3O2.Na
Molecular Weight 477.454
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PRADIGASTAT SODIUM

SMILES

[Na+].[O-]C(=O)C[C@H]1CC[C@@H](CC1)C2=CC=C(C=C2)C3=CC=C(NC4=CC=C(N=C4)C(F)(F)F)C=N3

InChI

InChIKey=MUZRGKSNUTWRAF-BHQIMSFRSA-M
InChI=1S/C25H24F3N3O2.Na/c26-25(27,28)23-12-10-21(15-30-23)31-20-9-11-22(29-14-20)19-7-5-18(6-8-19)17-3-1-16(2-4-17)13-24(32)33;/h5-12,14-17,31H,1-4,13H2,(H,32,33);/q;+1/p-1/t16-,17-;

HIDE SMILES / InChI

Molecular Formula C25H23F3N3O2
Molecular Weight 454.4642
Charge -1
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://adisinsight.springer.com/drugs/800030516

LCQ908 (Pradigastat) is a diacylglycerol acyltransferase-1 (DGAT-1) inhibitor. DGAT-1 is one of the two DGAT enzymes that catalyse the formation of triglycerides from diacylglycerol and acyl- coenzyme A. DGAT-1 catalyses the final committed step in processing dietary fatty acids into triglycerides carried on chylomicrons for transport around the body. Pradigastat may decrease the level of triglycerides in the blood and is intended for the first line treatment of FCS. It is administered orally at 10-40mg daily in addition to a low fat diet. Pradigastat is also in phase II clinical trials for type 2 diabetes and severe hypertriglyceridaemia (familial hyperchylomicronaemia phenotypes I and V). Pradigastat is a designated orphan drug in the EU. In a phase III clinical trial.

Originator

Curator's Comment: # Novartis

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1065 ng/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PRADIGASTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: FASTED
184 ng/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PRADIGASTAT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
10500 ng/mL
115 mg single, intravenous
dose: 115 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PRADIGASTAT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
18561 ng × h/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PRADIGASTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: FASTED
37200 ng × h/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PRADIGASTAT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
428000 ng × h/mL
115 mg single, intravenous
dose: 115 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PRADIGASTAT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
80.2 h
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PRADIGASTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: FASTED
145 h
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PRADIGASTAT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
109 h
115 mg single, intravenous
dose: 115 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PRADIGASTAT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
0.6%
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PRADIGASTAT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
300 mg single, oral
Highest studied dose
Dose: 300 mg
Route: oral
Route: single
Dose: 300 mg
Sources: Page: p.1037
unhealthy, ADULT
n = 8
Health Status: unhealthy
Condition: obesity
Age Group: ADULT
Sex: M
Food Status: FASTED
Population Size: 8
Sources: Page: p.1037
115 mg single, intravenous
Studied dose
Dose: 115 mg
Route: intravenous
Route: single
Dose: 115 mg
Sources: Page: p.9
healthy, ADULT
n = 9
Health Status: healthy
Age Group: ADULT
Sex: M+F
Food Status: FASTED
Population Size: 9
Sources: Page: p.9
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

Experimental: LCQ908 (Pradigastat) 20 mg In period II (0-12 weeks) double-blind treatment: one LCQ908 (Pradigastat) 20 mg active tablet, once daily In period III (12-52 weeks) double blind treatment: Without down titration, the period II dosing regimen will follow. Following decision to down titrate: one LCQ908 (Pradigastat) 10 mg active tablet, once daily.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: In vitro, pradigastat significantly reduced Hepatitis C virus production, consistent with inhibition of viral assembly and release.
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 16 00:14:07 UTC 2023
Edited
by admin
on Sat Dec 16 00:14:07 UTC 2023
Record UNII
X0EWE8TT2H
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PRADIGASTAT SODIUM
USAN  
USAN  
Official Name English
LCQ908A
Code English
LCQ-908 SODIUM SALT
Common Name English
PRADIGASTAT SODIUM [USAN]
Common Name English
LCQ-908A
Common Name English
LCQ-908-ABA
Code English
LCQ908-ABA
Code English
CYCLOHEXANEACETIC ACID, 4-(4-(5-((6-(TRIFLUOROMETHYL)-3-PYRIDINYL)AMINO)-2-PYRIDINYL)PHENYL)-, SODIUM SALT (1:1), TRANS-
Common Name English
LCQ-908ABA
Code English
Code System Code Type Description
CAS
956136-98-4
Created by admin on Sat Dec 16 00:14:08 UTC 2023 , Edited by admin on Sat Dec 16 00:14:08 UTC 2023
PRIMARY
PUBCHEM
53387034
Created by admin on Sat Dec 16 00:14:08 UTC 2023 , Edited by admin on Sat Dec 16 00:14:08 UTC 2023
PRIMARY
SMS_ID
100000183197
Created by admin on Sat Dec 16 00:14:08 UTC 2023 , Edited by admin on Sat Dec 16 00:14:08 UTC 2023
PRIMARY
FDA UNII
X0EWE8TT2H
Created by admin on Sat Dec 16 00:14:08 UTC 2023 , Edited by admin on Sat Dec 16 00:14:08 UTC 2023
PRIMARY
EU-Orphan Drug
EU/3/12/1036 (POSITIVE)
Created by admin on Sat Dec 16 00:14:08 UTC 2023 , Edited by admin on Sat Dec 16 00:14:08 UTC 2023
PRIMARY Treatment of familial chylomicronaemia syndrome (type-I hyperlipoproteinaemia).
USAN
AB-09
Created by admin on Sat Dec 16 00:14:08 UTC 2023 , Edited by admin on Sat Dec 16 00:14:08 UTC 2023
PRIMARY
NCI_THESAURUS
C170340
Created by admin on Sat Dec 16 00:14:08 UTC 2023 , Edited by admin on Sat Dec 16 00:14:08 UTC 2023
PRIMARY
ChEMBL
CHEMBL2364624
Created by admin on Sat Dec 16 00:14:08 UTC 2023 , Edited by admin on Sat Dec 16 00:14:08 UTC 2023
PRIMARY
EVMPD
SUB197601
Created by admin on Sat Dec 16 00:14:08 UTC 2023 , Edited by admin on Sat Dec 16 00:14:08 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY